CA-NEXA3D
6.9.2022 16:01:47 CEST | Business Wire | Press release
Nexa3D, the leading maker of ultrafast professional and industrial polymer 3D printers, today announced its plans to exhibit at IMTS, taking place September 12-17 in Chicago, Illinois. For its first showing at IMTS, Nexa3D is bringing its full – and rapidly expanding - additive manufacturing portfolio to Chicago.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005132/en/
The full suite of Nexa3D additive manufacturing solutions will be showcased at IMTS 2022, Additive Manufacturing Pavilion, Booth #432504 (Photo: Business Wire)
Among the real-world use cases highlighted at the booth will be the work with Applied Rapid Technologies (ART), where Nexa3D will demonstrate the benefits of owning the industrial 3D printing fleet for an on-demand manufacturing operation that replaces traditional urethane casting. Ultrafast, high performance resin 3D printing enables companies like ART to serve its customers’ needs in a more cost-effective manner and at a fraction of the time typically associated with traditional manufacturing methods. “Being a service provider with the Nexa3D machines - having 8 of them online now - just gives us more flexibility to take on projects and turn them around quickly. For years, we called this rapid prototyping, but it has really morphed into additive manufacturing,” said Bruce LeMaster, Vice President of Manufacturing at Obsidian Solutions Group.
“Nexa3D’s rapidly expanding product portfolio of ultrafast industrial solutions for the entire product life cycle democratizes access to industrial strength additive manufacturing tools, materials, and workflows for the benefit of small and large users. With no end in sight to persisting supply chain shortages, small and large product companies are more ready than ever before to explore digital manufacturing solutions and we are here to assist,” said Avi Reichental, CEO, and co-founder of Nexa3D.
Nexa3D’s end-to-end validated workflows, comprising its NexaX software platform, expanding functional polymer materials, and automated post processing deliver orders of magnitude better throughput and total cost of ownership advantages to businesses that are seeking to nearshore or localize parts of their supply chain operations. The company plans to showcase its latest industrial shop printers including its flagship NXE 400 and NXE 200 ultrafast 3D printers alongside its xCure, and xClean post-processing tools. The company also plans to introduce several new functional resins at the show.
As part of its rapidly expanding portfolio of manufacturing solutions, Nexa3D also plans to demonstrate the full power of its ultrafast XiP 3D printer in a production cell configuration, showcasing industry leading throughput, cost effectiveness, and functional material selection, powered by its open source platform enabling hyperlocal, flexible manufacturing.
The company plans to commercially launch previously announced QLS 820 high-productivity industrial sintering solution along with a powder processing system at IMTS. Designed for higher operating temperatures and broader powder processing windows, the QLS 820 offers the highest part throughput in its class, delivering unprecedented production throughput and flexibility. The system is a compelling alternative to traditional injection molding, designed with integration-ready Industry 4.0, lights-out manufacturing capabilities.
Nexa3D plans to take center stage on Wednesday, Sept. 14 at 1:00PM alongside its customer, PepsiCo, to talk about the latest manufacturing innovations in packaging design and development made possible by its ultrafast NXE 400 3D printers. More information and registration details available here.
As part of IMTS, the company plans to make several significant product commercialization announcements throughout the week from the show floor.
To learn more about the additive manufacturing solutions Nexa3D plans to exhibit at IMTS view the media kit.
About Nexa3D
Nexa3D is passionate about digitizing supply chains sustainably. The company makes ultrafast polymer 3D printers that deliver up to 20x productivity gains to professionals and businesses of all sizes. Partnerships with world-class material suppliers and its open materials platform unlock the full potential of additively manufactured polymers for volume production. Automated software tools optimize the entire production cycle using process interplay algorithms that ensure part performance and production consistency, while reducing waste, energy, and minimizing carbon footprints.
For more information on Nexa3D and its products, visit the Nexa3D website, or connect socially on LinkedIn, Twitter, Facebook, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom